Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INSPIRE phase 3 study of dersimelagon phosphate in EPP/XLP
NL-OMON60928Phase 3Completed
- Sponsor
- Mitsubishi Tanabe Pharma America
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dersimelagon in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), sponsored by Mitsubishi Tanabe Pharma America. Primary endpoint: Change from baseline in average daily sunlight exposure time to first prodromal symptom. Started Apr 2024; status: completed.
02
Drugs
dersimelagon
03
Conditions
erythropoietic protoporphyria (EPP)X-linked protoporphyria (XLP)
Beyond the preview
Go deeper on NL-OMON60928.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60928.